A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Inclusion Criteria Part A

* Participant has one of the selected solid tumors with no distant metastases, and is more than 8 weeks from completion of definitive therapy with intention to cure. Selected Solid Tumors: Stage I to III non-small cell lung carcinoma (NSCLC); Stage III breast cancer; Stage IIB or III melanoma; Stage II or III upper gastrointestinal tract carcinoma (e.g., esophagus, stomach, gallbladder, pancreas); Stage III colon carcinoma; Stage II, III, or IV (M0 only) renal cell carcinoma; Stage II, III, or IV (M0 only) bladder carcinoma; clinically-localized prostate carcinoma
* Participant has adequate organ function.
* Female participant of childbearing potential has a negative serum pregnancy test within 3 days of study enrollment.

Exclusion Criteria Part A

* Participant has known hypersensitivity to any component of study vaccine.
* Participant has a history of clinically significant cardiac conditions, including cardiac arrhythmias which have not been controlled within the last 3 months, unstable angina, myocardial infarction (within the last 3 months), or New York Heart Association (NYHA) Class III or IV congestive heart failure. Participant must have no clinically significant electrocardiogram (ECG) abnormalities and not have a pacemaker or cardioverter/defibrillator implanted.
* Participant has undergone splenectomy or has any history of autoimmune disorder.
* Participant has received immunosuppressive treatment within 1 month prior to enrollment.
* Participant has known acquired, inherited, or idiopathic thrombocytopenia, platelet dysfunction or coagulopathy that would contraindicate IM injections.
* Participant has an acute infection requiring intravenous antibiotic, antiviral or antifungal agents within 2 weeks of study entry.
* Participant is pregnant or breastfeeding, or expecting to conceive at any time during the study or within 1 year after receiving the last vaccination.
* Participant is known to be Human Immunodeficiency Virus (HIV)-seropositive.
* Participant has known history of Hepatitis B or C or active Hepatitis A.
* Participant has been vaccinated for any disease or for prophylaxis within 1 month prior to the first vaccination.
* The participant has been diagnosed with Systemic Lupus Erythematosus (SLE)

Inclusion Criteria Part B

* Participant must have completed their respective vaccination Treatment Group regimen for Part A of this study.
* Participant must have completed a ≥12 week safety observation period prior to receiving their first V934-EP boost.

Exclusion Criteria Part B

* Participant has new or metastatic tumor lesions since enrollment in Part A.
* Participant has developed any significant cardiac conditions since enrollment in Part A including cardiac arrhythmias which have not been controlled within the last 3 months, unstable angina, myocardial infarction (within the last 3 months), or NYHA Class III or IV congestive heart failure.
* Participant has undergone a splenectomy, or has developed any autoimmune disorders, since enrollment in Part A.
* Participant has received immunosuppressive treatment within 1 month prior to enrollment in Part B
* Participant has developed any acquired, inherited, or idiopathic thrombocytopenia, platelet dysfunction or coagulopathy that would contraindicate IM injections
* Participant has an acute infection requiring intravenous antibiotic, antiviral or antifungal agents within 2 weeks of entry to Part B.